{
  "success": true,
  "pagesUsed": [
    2,
    4,
    10,
    12,
    15,
    17,
    20,
    25,
    27,
    29,
    32,
    37,
    39,
    40,
    41,
    42,
    57
  ],
  "modelUsed": "gemini-2.5-pro",
  "confidence": 1.0,
  "scheduling": {
    "timings": [
      {
        "id": "timing_1",
        "name": "End of Study Visit Window",
        "type": "At",
        "unit": "days",
        "instanceType": "Timing",
        "value": 54,
        "relativeTo": "First Dose",
        "windowLower": -2,
        "windowUpper": 2
      },
      {
        "id": "timing_2",
        "name": "Zinc Washout Period",
        "type": "Before",
        "unit": "days",
        "instanceType": "Timing",
        "value": 21,
        "relativeTo": "First Dose"
      },
      {
        "id": "timing_3",
        "name": "Chelator Washout Period",
        "type": "Before",
        "unit": "days",
        "instanceType": "Timing",
        "value": 4,
        "relativeTo": "First Dose"
      },
      {
        "id": "timing_4",
        "name": "Experimental Therapy Washout",
        "type": "Before",
        "unit": "days",
        "instanceType": "Timing",
        "value": 90,
        "relativeTo": "Screening"
      },
      {
        "id": "timing_5",
        "name": "Prescription Medication Washout",
        "type": "Before",
        "unit": "days",
        "instanceType": "Timing",
        "value": 14
      },
      {
        "id": "timing_6",
        "name": "Non-Prescription Medication Washout",
        "type": "Before",
        "unit": "days",
        "instanceType": "Timing",
        "value": 7
      },
      {
        "id": "timing_7",
        "name": "Run-in Period",
        "type": "Between",
        "unit": "days",
        "instanceType": "Timing",
        "value": -7,
        "relativeTo": "First Dose"
      },
      {
        "id": "timing_8",
        "name": "Baseline Balance Measurement Period",
        "type": "Between",
        "unit": "days",
        "instanceType": "Timing",
        "value": -4,
        "relativeTo": "First Dose"
      },
      {
        "id": "timing_9",
        "name": "15 mg/day Dosing Period",
        "type": "Between",
        "unit": "days",
        "instanceType": "Timing",
        "value": 1,
        "relativeTo": "First Dose"
      },
      {
        "id": "timing_10",
        "name": "30 mg/day Dosing Period",
        "type": "Between",
        "unit": "days",
        "instanceType": "Timing",
        "value": 29,
        "relativeTo": "First Dose"
      },
      {
        "id": "timing_11",
        "name": "Outpatient Period Extension",
        "type": "Within",
        "unit": "days",
        "instanceType": "Timing",
        "value": 14
      },
      {
        "id": "timing_12",
        "name": "Post-dose Meal Delay",
        "type": "After",
        "unit": "hours",
        "instanceType": "Timing",
        "value": 2
      },
      {
        "id": "timing_13",
        "name": "Overnight Fast",
        "type": "Before",
        "unit": "hours",
        "instanceType": "Timing",
        "value": 10
      },
      {
        "id": "timing_14",
        "name": "Outpatient Dosing Time Window",
        "type": "At",
        "unit": "hours",
        "instanceType": "Timing",
        "value": 0,
        "windowLower": -1,
        "windowUpper": 1
      }
    ],
    "conditions": [
      {
        "id": "cond_1",
        "name": "Moderate ALT Elevation",
        "instanceType": "Condition",
        "description": "Criteria for dose interruption due to liver enzyme elevation.",
        "text": "ALT > 3 × ULN and ≤ 5 × ULN"
      },
      {
        "id": "cond_2",
        "name": "Severe ALT Elevation",
        "instanceType": "Condition",
        "description": "Criteria for permanent discontinuation due to liver enzyme elevation.",
        "text": "ALT > 5 × ULN"
      },
      {
        "id": "cond_3",
        "name": "Low Hemoglobin",
        "instanceType": "Condition",
        "description": "Criteria for dose reduction due to low hemoglobin.",
        "text": "Hemoglobin < 10 g/dL"
      },
      {
        "id": "cond_4",
        "name": "Low Platelets",
        "instanceType": "Condition",
        "description": "Criteria for dose reduction due to low platelets.",
        "text": "Platelets < 100,000/mm3"
      },
      {
        "id": "cond_5",
        "name": "Neutrophil Decrease",
        "instanceType": "Condition",
        "description": "Criteria for dose reduction due to significant neutrophil decrease.",
        "text": "Neutrophils > 30% decrease from baseline and below reference range at baseline"
      },
      {
        "id": "cond_6",
        "name": "Hy's Law Criteria",
        "instanceType": "Condition",
        "description": "Criteria for dose interruption due to potential liver injury.",
        "text": "Bilirubin > 2 × ULN accompanied by ALT > 3 × ULN"
      },
      {
        "id": "cond_7",
        "name": "Neurologic Worsening",
        "instanceType": "Condition",
        "description": "Criteria for potential dose modification based on neurologic assessment.",
        "text": "Evidence of neurologic worsening by AEs or by neurologic physical exam assessment"
      },
      {
        "id": "cond_8",
        "name": "Psychiatric Worsening",
        "instanceType": "Condition",
        "description": "Criteria for potential dose modification based on psychiatric assessment.",
        "text": "Evidence of clinically significant acute psychiatric worsening which may include but not limited to suicidality, acute depression, or psychosis."
      },
      {
        "id": "cond_9",
        "name": "Acceptable Safety for Dose Escalation",
        "instanceType": "Condition",
        "description": "Safety Review Committee must review safety data through Day 23 before dose escalation.",
        "text": "Review of available safety data through Day 23 by the Safety Review Committee (SRC) shows no safety concerns precluding dose increase."
      },
      {
        "id": "cond_10",
        "name": "Discontinuation Criteria",
        "instanceType": "Condition",
        "description": "General criteria for discontinuing study intervention.",
        "text": "Serious hypersensitivity reaction; Severe uncontrolled infection; Use of disallowed medication; Pregnancy or planned pregnancy."
      }
    ],
    "conditionAssignments": [],
    "transitionRules": [
      {
        "id": "trans_1",
        "name": "Dose Escalation to 30mg",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "fromElementId": "dose_15mg",
        "toElementId": "dose_30mg",
        "text": "On Day 29, increase dose from 15 mg/day to 30 mg/day, following SRC review of safety data through Day 23."
      },
      {
        "id": "trans_2",
        "name": "Dose Interruption for Moderate ALT Elevation",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "text": "Temporary interruption of dosing if ALT > 3 × ULN and ≤ 5 × ULN."
      },
      {
        "id": "trans_3",
        "name": "Discontinuation for Severe ALT Elevation",
        "instanceType": "TransitionRule",
        "transitionType": "Discontinuation",
        "text": "Permanently discontinue study intervention if ALT > 5 × ULN."
      },
      {
        "id": "trans_4",
        "name": "Dose Reduction for Hematologic Abnormality",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "text": "Reduce dose to previous dose level or to 15 mg QOD if Hemoglobin < 10 g/dL, Platelets < 100,000/mm3, or Neutrophils > 30% decrease from baseline."
      },
      {
        "id": "trans_5",
        "name": "Dose Interruption for Hy's Law Criteria",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "text": "Temporary interruption of dosing if Bilirubin > 2 × ULN accompanied by ALT > 3 × ULN."
      },
      {
        "id": "trans_6",
        "name": "Dose Modification for Neurologic/Psychiatric Worsening",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "text": "Investigator and Alexion Medical Monitor will evaluate the need for dose modification (interruption, increase or decrease) based on neurologic or psychiatric worsening."
      },
      {
        "id": "trans_7",
        "name": "Intervention Discontinuation for Safety/Compliance",
        "instanceType": "TransitionRule",
        "transitionType": "Discontinuation",
        "text": "Participants must be considered for discontinuation from study intervention for: Serious hypersensitivity reaction; Severe uncontrolled infection; Use of disallowed medication; Pregnancy or planned pregnancy."
      }
    ],
    "scheduleTimelineExits": [
      {
        "id": "exit_1",
        "name": "Study Completion",
        "exitType": "Completion",
        "instanceType": "ScheduleTimelineExit",
        "description": "A participant is considered to have completed the study if he/she has completed all phases of the study including the last scheduled procedure shown in the Schedule of Activities (SoA)."
      },
      {
        "id": "exit_2",
        "name": "Participant Withdrawal of Consent",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "A participant may withdraw from the study at any time at his/her own request."
      },
      {
        "id": "exit_3",
        "name": "Investigator Discretionary Withdrawal",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "A participant may be withdrawn at any time at the discretion of the Investigator for safety, behavioral, compliance, or administrative reasons."
      },
      {
        "id": "exit_4",
        "name": "Lost to Follow-up",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "A participant will be considered lost to follow-up if he or she repeatedly fails to return for scheduled visits and is unable to be contacted by the study site."
      },
      {
        "id": "exit_5",
        "name": "Sponsor or Investigator Termination of Study/Site",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "The study or a site may be closed early for reasons including failure to comply with protocol, inadequate recruitment, or discontinuation of study intervention development."
      }
    ],
    "scheduledDecisionInstances": [
      {
        "id": "dec_1",
        "name": "Dose Escalation Decision",
        "timepointId": "Day 23",
        "instanceType": "ScheduledDecisionInstance",
        "description": "Safety Review Committee (SRC) reviews safety data through Day 23 to approve dose titration from 15 mg/day to 30 mg/day on Day 29.",
        "conditionIds": [
          "cond_9"
        ]
      },
      {
        "id": "dec_2",
        "name": "Ongoing Safety-Based Dose Modification",
        "timepointId": "Ongoing",
        "instanceType": "ScheduledDecisionInstance",
        "description": "At any time, if a participant meets criteria for dose modification (e.g., elevated LFTs, hematologic abnormalities, neurologic/psychiatric worsening), the dose will be modified or interrupted as specified.",
        "conditionIds": [
          "cond_1",
          "cond_2",
          "cond_3",
          "cond_4",
          "cond_5",
          "cond_6",
          "cond_7",
          "cond_8"
        ]
      },
      {
        "id": "dec_3",
        "name": "Ongoing Intervention Discontinuation Decision",
        "timepointId": "Ongoing",
        "instanceType": "ScheduledDecisionInstance",
        "description": "At any time, if a participant meets criteria for intervention discontinuation (e.g., severe ALT elevation, hypersensitivity, pregnancy), the study intervention will be permanently discontinued.",
        "conditionIds": [
          "cond_2",
          "cond_10"
        ]
      }
    ],
    "summary": {
      "timingCount": 14,
      "conditionCount": 10,
      "transitionRuleCount": 7,
      "exitCount": 5
    }
  }
}